A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors

NCT02232620 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Low feasibility

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG: BBI503

Sponsor

Sumitomo Pharma America, Inc.